Long-term remission with rituximab in refractory leucine-rich glioma inactivated 1 antibody encephalitis
- 1 June 2014
- journal article
- case report
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 271 (1-2) , 66-68
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Anti–B Cell Antibody Therapies for Inflammatory Rheumatic DiseasesAnnual Review of Medicine, 2014
- VGKC-complex/LGI1-antibody encephalitis: Clinical manifestations and response to immunotherapyJournal of Neuroimmunology, 2013
- Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotypeBrain, 2013
- Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort studyThe Lancet Neurology, 2013
- Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan’s syndrome and acquired neuromyotoniaBrain, 2010
- Rituximab in the treatment of three coexistent neurological autoimmune diseases: chronic inflammatory demyelinating polyradiculoneuropathy, Morvan syndrome and myasthenia gravisJournal of Neurology, Neurosurgery & Psychiatry, 2010
- Long‐term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re‐treatmentArthritis & Rheumatism, 2006
- Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosusArthritis & Rheumatism, 2004
- Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid ArthritisNew England Journal of Medicine, 2004
- Potassium channel antibody‐associated encephalopathy: a potentially immunotherapy‐responsive form of limbic encephalitisBrain, 2004